PlantEXT is an early mover in medical cannabis research and development backed by advanced science and clinical studies in Israel. As a global leader in developing medical cannabis products, PlantEXT is unlocking the anti-inflammatory benefits of medical cannabis through our proprietary research and technology platform.
Our company was founded in 2015 by Dr. Oded Sagee as a wholly owned subsidiary of Israel Plant Sciences Limited. This strategic partnership held an exclusive licence agreement to conduct medical cannabis research and development with the world-class Agricultural Research Organization (“ARO”) of the State of Israel. The research is conducted in the laboratory of Dr. Hinanit Koltai, a world leader in medical cannabis research.
In 2017, PlantEXT entered the next phase, with investment from medical cannabis trailblazers with expertise in the Canadian private and public sectors. We began assembling an industry-leading product development and commercialization team led by Douglas Sommerville, a pharma industry veteran. Doug was the former Country Head in Canada for Teva, an Israel-based, global pharmaceutical company. During Doug’s 14-year tenure, Teva recorded record profits and became strongly positioned as the market leader.
Today, from our dedicated research laboratories in Israel, the PlantEXT research team is positioned at the forefront of science-based medical cannabis product development. PlantEXT’s technology isolates therapeutic extract fractions and quantifies anti-inflammatory activity through in vitro and ex vivo studies, and through small-animal studies.
PlantEXT’s first product is a treatment for inflammatory bowel disease under licence from ARO and will be marketed for sale beginning in early 2019. In addition, PlantEXT’s independently developed products will come to market beginning in 2019.